All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @ojayto on TikTok · 30s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @ojayto's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Alright, so how do you do the backwater and how do you figure out how much to mix with the
  2. 0:03retitrutide?
  3. 0:04This is where a lot of people mess up, so I'm going to show you exactly what to do.
  4. 0:07So right here I have a 5 milligram vial of retitrutide, and it's still in its powdered
  5. 0:11form which means I have not added backwater yet.
  6. 0:14Since it's a 5 milligram vial, I'm going to add 1 milliliter of backwater.
  7. 0:18That way every 20 units on my syringe is going to be a 1 milligram dose.
  8. 0:21100 units divided by 5 being 20 units.
  9. 0:24And then for a 10 milligram vial, you would add 2 milliliters of backwater.
  10. 0:28If you guys have any more questions, leave them in the comments.

@ojayto's peptide claims need serious fact-checking

OT Peptides

TikTok creator

186.0K viewsWatch on TikTok

Quick answer

Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon receptors) that showed significant weight loss in a 2023 Phase 2 trial (Jastreboff et al., NEJM) but has not received FDA approval. The reconstitution ratio described in the video is mathematically correct for a standard 1 mL bacteriostatic water dilution, but the video omits storage requirements, sterile handling technique, and any clinical supervision context. Compounded or research-grade retatrutide cannot be assumed to match the purity or potency of the pharmaceutical formulation studied in clinical trials.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @ojayto's peptide claims need serious fact-checking, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@ojayto's peptide claims need serious fact-checking is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@ojayto's peptide claims need serious fact-checking" from OT Peptides. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon receptors) that showed significant weight loss in a 2023 Phase 2 trial (Jastreboff et al.

The reason this review is not generic is the source wording and the canonical claim label "peptides replying to hahah health fitness fyp." In this clip, the useful excerpt is: "Alright, so how do you do the backwater and how do you figure out how much to mix with the retitrutide?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Retatrutide is not FDA-approved.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon receptors) that showed significant weight loss in a 2023 Phase 2 trial (Jastreboff et al.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Retatrutide is an investigational triple agonist (GIP, GLP-1, glucagon receptors) that showed significant weight loss in a 2023 Phase 2 trial (Jastreboff et al., NEJM) but has not received FDA approval. The reconstitution ratio described in the video is mathematically correct for a standard 1 mL bacteriostatic water dilution, but the video omits storage requirements, sterile handling technique, and any clinical supervision context. Compounded or research-grade retatrutide cannot be assumed to match the purity or potency of the pharmaceutical formulation studied in clinical trials.
  • The 1 mL per 5 mg vial reconstitution ratio is mathematically correct and produces a 5 mg/mL concentration where 20 units on a U-100 syringe equals 1 mg.
  • Retatrutide is not FDA-approved. As of the 2023 Phase 2 NEJM publication (Jastreboff et al.), it remains investigational and is only available through compounding pharmacies or unregulated research suppliers.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The 1 mL per 5 mg vial reconstitution ratio is mathematically correct and produces a 5 mg/mL concentration where 20 units on a U-100 syringe equals 1 mg.
  • Retatrutide is not FDA-approved. As of the 2023 Phase 2 NEJM publication (Jastreboff et al.), it remains investigational and is only available through compounding pharmacies or unregulated research suppliers.
  • Compounded peptides are not pharmaceutical equivalents. Purity, sterility, and potency vary and cannot be confirmed without third-party certificates of analysis from the supplying lab.
  • Bacteriostatic water has its own handling requirements. Once opened, it should be used within 28 days, stored appropriately, and drawn with sterile technique to avoid contamination.
  • After reconstitution, peptide vials generally require refrigeration and should be used within 28-30 days. The video mentions none of this.
  • The Phase 2 trial showing 24.2% average body weight loss used dose escalation under medical supervision, not a flat self-selected dose drawn from a home-mixed vial.
  • Any use of injectable, unregulated compounds carries infection risk, dosing error risk, and unknown long-term safety profiles. A licensed clinician should be involved before starting any such protocol.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @ojayto actually say?

The creator walked viewers through reconstituting retatrutide powder using bacteriostatic water, explaining a simple ratio: add 1 mL of bacteriostatic water to a 5 mg vial so that "every 20 units on my syringe is going to be a 1 milligram dose." For a 10 mg vial, they said to use 2 mL. That is essentially the whole video.

What the video does not say is also important. There is no mention of what retatrutide actually is, no discussion of who it is intended for, no sourcing guidance, no storage instructions after reconstitution, and no acknowledgment that this compound is not FDA-approved and is only available as a compounded or research-grade substance. The video is framed as a helpful how-to, but it skips essentially every safety-relevant detail.

Does the science back this up?

The reconstitution math itself is correct. The dosing arithmetic the creator describes is standard pharmacy-level dilution logic and does not require a study to validate. However, the broader context of retatrutide use is where things get complicated.

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. In a 2023 Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023, NEJM), participants receiving 12 mg weekly doses lost an average of 24.2% of body weight over 48 weeks, which was notable. But that trial used a specific pharmaceutical-grade formulation administered under medical supervision with dose escalation protocols. The compound available through compounding pharmacies or gray-market peptide suppliers is not the same product used in those trials. Potency, purity, and sterility cannot be assumed equivalent.

What did they get wrong (or right)?

The math is right. 1 mL into a 5 mg vial does yield 1 mg per 20 units on a standard U-100 insulin syringe. Credit where it is due.

But the framing is the problem. The creator presents this as a routine skill anyone can pick up from a TikTok, with no acknowledgment of the risks involved in self-injecting an unregulated compound. There is no mention of injection site care, no guidance on recognizing adverse reactions like nausea, tachycardia, or hypoglycemia, and no recommendation to involve a clinician.

More specifically, the video does not address:

  • The difference between pharmaceutical-grade and compounded or research-grade retatrutide
  • Storage requirements after reconstitution (typically refrigerated, used within 28-30 days)
  • That "backwater" (bacteriostatic water) itself has a shelf life and must be handled with sterile technique
  • That retatrutide has not received FDA approval as of this writing

Getting the dilution ratio right while ignoring everything else is a partial credit situation at best.

What should you actually know?

Retatrutide is one of the more aggressively studied GLP-1-class compounds in the pipeline, and the Phase 2 data is genuinely interesting to researchers and clinicians. But interesting Phase 2 data is not the same as an approved, safety-characterized treatment.

The reconstitution technique shown here, mixing lyophilized peptide with bacteriostatic water and drawing doses with an insulin syringe, is a real practice in clinical and compounding contexts. Done correctly under proper guidance, it is a learnable skill. Done incorrectly or with contaminated supplies, it carries real infection and dosing error risks.

If you are considering any GLP-1-class peptide therapy, including retatrutide, the starting point should be a licensed clinician who can evaluate your health history, monitor for side effects, and source compounds from a verified, regulated pharmacy. A TikTok comment section is not a substitute for that process.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

OT Peptides · TikTok creator

186.0K views on this video

Replying to @hahah #health #fitness #fyp

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the 1 ml per 5 mg vial reconstitution ratio?

The 1 mL per 5 mg vial reconstitution ratio is mathematically correct and produces a 5 mg/mL concentration where 20 units on a U-100 syringe equals 1 mg.

What does the video say about retatrutide?

Retatrutide is not FDA-approved. As of the 2023 Phase 2 NEJM publication (Jastreboff et al.), it remains investigational and is only available through compounding pharmacies or unregulated research suppliers.

What does the video say about compounded peptides?

Compounded peptides are not pharmaceutical equivalents. Purity, sterility, and potency vary and cannot be confirmed without third-party certificates of analysis from the supplying lab.

What does the video say about bacteriostatic water has its own handling requirements. once opened, it?

Bacteriostatic water has its own handling requirements. Once opened, it should be used within 28 days, stored appropriately, and drawn with sterile technique to avoid contamination.

What does the video say about after reconstitution, peptide vials generally require refrigeration?

After reconstitution, peptide vials generally require refrigeration and should be used within 28-30 days. The video mentions none of this.

What does the video say about the phase 2 trial showing 24.2% average body weight loss?

The Phase 2 trial showing 24.2% average body weight loss used dose escalation under medical supervision, not a flat self-selected dose drawn from a home-mixed vial.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by OT Peptides, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.